资讯
内科
心血管
肿瘤
内分泌
普通内科
消化
呼吸
神经科
传染科
精神心理
肾内科
风湿免疫
血液科
老年医学
外科
头颈外科
胃肠外科
血管外科
肝胆胰外
骨科
普通外科
胸心外科
神经外科
泌尿外科
烧伤科
整形美容
麻醉疼痛
专科科室
罕见病
康复医学
药械
儿科
耳鼻咽喉
口腔科
眼科
政策人文
营养全科
预防公卫
妇产科
中医科
急重症
皮肤性病
影像放射
转化医学
检验病理
护理
热点
临床研究
研究设计
人工智能
智慧医疗
论文基金
医学科普
药物经济
医生集团
职业安全
患者招募
医学科研
公司产业
医学英语
MedSci动态
指南
按科室浏览
肿瘤科
心血管
传染科
妇产科
神经科
儿科
呼吸
内分泌科
血液科
消化
更多科室
工具
临床工具
临床指南
医学计算与公式
ICD-10/ICD-11疾病编码
医迅达
直播
话题
公开课
精品课
科研工具
期刊数据库查询
期刊智能选择
全球基金查询
文献查询
SCI写作宝典
生物医药大词典
其他工具
下载App使用方便更快捷
Medsci 梅斯搜索
公开课
精品课
服务
科研数智化
直播,公开课与精品课
科研加速器
研究者发起的临床研究(IIS)支持
真实世界研究解决方案
药物经济学
医保准入事务
研究方案设计
数据库建立与管理
药物警戒(PV)
真实世界研究执行
数据统计分析
数字化学术传播解决方案
多渠道营销(MCM)
产品医学策略
学术传播(APO)
其它
积分商城
FAQS
map
#BMS#
60篇内容 | 1718人围观
关注话题
话题活跃用户
#
插入话题
插入图片
评论
最新
最热
GetTopicDetailResponse(id=f238358866, topicName=BMS, introduction=BMS, content=null, image=null, comments=60, allHits=1718, url=https://h5.medsci.cn/topic?id=3588, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=2379, tagList=[TagDto(tagId=2379, tagName=BMS)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1378691, encodeId=6a6a13e8691e2, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=BMS获得欧盟委员会对CAR-T疗法Breyanzi的支持, objectType=article, longId=295110, objectId=31a329511012, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31a329511012, replyNumber=0, likeNumber=97, createdTime=2022-02-05, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31a329511012, moduleTitle=BMS获得欧盟委员会对CAR-T疗法Breyanzi的支持, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=31a329511012)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378690, encodeId=21c613e86909d, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=Journal Endovascular Therapy:DCB和BMS治疗股腘动脉病变,术后TLR发生率无差异?, objectType=article, longId=293597, objectId=44cf29359e24, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44cf29359e24, replyNumber=0, likeNumber=128, createdTime=2022-01-09, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44cf29359e24, moduleTitle=Journal Endovascular Therapy:DCB和BMS治疗股腘动脉病变,术后TLR发生率无差异?, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=44cf29359e24)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378689, encodeId=b4f613e868983, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=J Immunother Cancer:黑素瘤脑转移(MBMs)患者一线BRAF- MEKi耐药后使用ipilimumab- nivolumab治疗效果差, objectType=article, longId=218646, objectId=e1fc218646bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1fc218646bf, replyNumber=0, likeNumber=70, createdTime=2021-10-17, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1fc218646bf, moduleTitle=J Immunother Cancer:黑素瘤脑转移(MBMs)患者一线BRAF- MEKi耐药后使用ipilimumab- nivolumab治疗效果差, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e1fc218646bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378688, encodeId=2c4113e86882f, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=BMS的CAR-T细胞疗法治疗多发性骨髓瘤,已获得FDA批准, objectType=article, longId=209107, objectId=d5a420910e55, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5a420910e55, replyNumber=0, likeNumber=64, createdTime=2021-03-29, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5a420910e55, moduleTitle=BMS的CAR-T细胞疗法治疗多发性骨髓瘤,已获得FDA批准, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=d5a420910e55)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378687, encodeId=787e13e868710, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=FDA接受BMS在梗阻性肥厚性心肌病(oHCM)中使用Mavacamten的申请, objectType=article, longId=208823, objectId=6828208823c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6828208823c0, replyNumber=0, likeNumber=133, createdTime=2021-03-23, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6828208823c0, moduleTitle=FDA接受BMS在梗阻性肥厚性心肌病(oHCM)中使用Mavacamten的申请, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=6828208823c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378686, encodeId=83d913e8686cc, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=131亿美元!BMS完成对MyoKardia的收购,获得心血管特效药mavacamten, objectType=article, longId=203521, objectId=7249203521e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7249203521e8, replyNumber=0, likeNumber=72, createdTime=2020-11-20, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7249203521e8, moduleTitle=131亿美元!BMS完成对MyoKardia的收购,获得心血管特效药mavacamten, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=7249203521e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378685, encodeId=41b313e8685d8, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=J Neurointerv Surg:药物涂层球囊治疗冠状动脉新生病变的效果并不劣于BMS或DES, objectType=article, longId=203301, objectId=ffa520330166, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffa520330166, replyNumber=0, likeNumber=85, createdTime=2020-11-14, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffa520330166, moduleTitle=J Neurointerv Surg:药物涂层球囊治疗冠状动脉新生病变的效果并不劣于BMS或DES, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ffa520330166)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378684, encodeId=5ce913e868448, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=BMS口服TYK2抑制剂deucravacitinib治疗斑块型银屑病3期临床成功! 效果优于apremilast, objectType=article, longId=202961, objectId=601d202961a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=601d202961a3, replyNumber=0, likeNumber=115, createdTime=2020-11-07, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=601d202961a3, moduleTitle=BMS口服TYK2抑制剂deucravacitinib治疗斑块型银屑病3期临床成功! 效果优于apremilast, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=601d202961a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378683, encodeId=f60613e8683b9, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=J Tissue Eng Regen Med:BMSCs衍生的外泌体对炎症和成骨的免疫调节作用, objectType=article, longId=201818, objectId=f0542018187a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0542018187a, replyNumber=0, likeNumber=67, createdTime=2020-10-09, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0542018187a, moduleTitle=J Tissue Eng Regen Med:BMSCs衍生的外泌体对炎症和成骨的免疫调节作用, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=f0542018187a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378682, encodeId=b6a713e868285, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=Cell Transplant:研究揭示αCGRP影响BMSCs迁移和成骨的机制, objectType=article, longId=201598, objectId=1d1c20159867, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d1c20159867, replyNumber=0, likeNumber=59, createdTime=2020-10-05, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d1c20159867, moduleTitle=Cell Transplant:研究揭示αCGRP影响BMSCs迁移和成骨的机制, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1d1c20159867)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378681, encodeId=da3e13e8681c9, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=Biomed Res Int:研究发现镁通过调整骨免疫调控增强BMSCs的成骨作用, objectType=article, longId=201596, objectId=2ed320159663, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ed320159663, replyNumber=0, likeNumber=80, createdTime=2020-10-05, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ed320159663, moduleTitle=Biomed Res Int:研究发现镁通过调整骨免疫调控增强BMSCs的成骨作用, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=2ed320159663)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378680, encodeId=413d13e86802b, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=吉利德Kite副总裁离职、拜耳CEO任期延长、BMS肿瘤研发首脑加入Blueprint……, objectType=article, longId=200934, objectId=8f8c200934f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f8c200934f5, replyNumber=0, likeNumber=100, createdTime=2020-09-21, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f8c200934f5, moduleTitle=吉利德Kite副总裁离职、拜耳CEO任期延长、BMS肿瘤研发首脑加入Blueprint……, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8f8c200934f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378679, encodeId=758313e8679ac, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=BMS的PD-1单抗Opdivo,获得FDA批准用于晚期食道鳞状细胞癌, objectType=article, longId=195725, objectId=0297195e2587, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0297195e2587, replyNumber=0, likeNumber=78, createdTime=2020-06-13, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0297195e2587, moduleTitle=BMS的PD-1单抗Opdivo,获得FDA批准用于晚期食道鳞状细胞癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=0297195e2587)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378678, encodeId=603d13e86787e, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=Stem Cells Int:PDGF-BB可增强BMSC的成骨和血管生成能力促进骨再生, objectType=article, longId=194951, objectId=bd5d19495199, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd5d19495199, replyNumber=0, likeNumber=72, createdTime=2020-05-31, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd5d19495199, moduleTitle=Stem Cells Int:PDGF-BB可增强BMSC的成骨和血管生成能力促进骨再生, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=bd5d19495199)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378677, encodeId=a50113e867739, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=肺癌一线免疫治疗!BMS明星免疫组合Opdivo+Yervoy获美国FDA批准第5个适应症,治疗转移性非小细胞肺癌患者!, objectType=article, longId=194364, objectId=22021943645c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22021943645c, replyNumber=0, likeNumber=109, createdTime=2020-05-20, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22021943645c, moduleTitle=肺癌一线免疫治疗!BMS明星免疫组合Opdivo+Yervoy获美国FDA批准第5个适应症,治疗转移性非小细胞肺癌患者!, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=22021943645c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378676, encodeId=b35d13e867604, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=BMS的PD-1单抗Opdivo首次获批治疗食道癌, objectType=article, longId=188791, objectId=aa9f188e91bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa9f188e91bf, replyNumber=0, likeNumber=69, createdTime=2020-02-27, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa9f188e91bf, moduleTitle=BMS的PD-1单抗Opdivo首次获批治疗食道癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=aa9f188e91bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378675, encodeId=e32513e86756c, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=JAMA Oncol:BMS-986156单药或联合纳武单抗治疗晚期实体肿瘤, objectType=article, longId=183395, objectId=5a5318339506, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a5318339506, replyNumber=0, likeNumber=56, createdTime=2019-11-23, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a5318339506, moduleTitle=JAMA Oncol:BMS-986156单药或联合纳武单抗治疗晚期实体肿瘤, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=5a5318339506)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378674, encodeId=3fa313e867445, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=BMS的Opdivo/Yervoy组合治疗肝细胞癌,获得FDA的优先审查, objectType=article, longId=183122, objectId=309218312237, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=309218312237, replyNumber=0, likeNumber=94, createdTime=2019-11-19, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=309218312237, moduleTitle=BMS的Opdivo/Yervoy组合治疗肝细胞癌,获得FDA的优先审查, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=309218312237)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378673, encodeId=0dcf13e86737c, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功, objectType=article, longId=181829, objectId=2a12181829fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a12181829fb, replyNumber=0, likeNumber=62, createdTime=2019-10-25, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a12181829fb, moduleTitle=BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=2a12181829fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1378672, encodeId=93cd13e8672ab, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, objectTitle=BMS和辉瑞宣布与Fitbit合作推动房颤可穿戴设备的及时诊断, objectType=article, longId=181604, objectId=b52018160411, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b52018160411, replyNumber=0, likeNumber=86, createdTime=2019-10-21, rootId=0, userName=canlab, userId=512d422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b52018160411, moduleTitle=BMS和辉瑞宣布与Fitbit合作推动房颤可穿戴设备的及时诊断, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=b52018160411)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
风湿免疫小助手
关注
已关注
BMS
2020-05-29
canlab
(审核中...)
关注
已关注
前往app查看评论内容
#BMS#
BMS获得欧盟委员会对CAR-T疗法Breyanzi的支持
97
0
2022-02-05
回复
canlab
(审核中...)
关注
已关注
前往app查看评论内容
#BMS#
Journal Endovascular Therapy:DCB和BMS治疗股腘动脉病变,术后TLR发生率无差异?
128
0
2022-01-09
回复
canlab
(审核中...)
关注
已关注
前往app查看评论内容
#BMS#
J Immunother Cancer:黑素瘤脑转移(MBMs)患者一线BRAF- MEKi耐药后使用ipilimumab- nivolumab治疗效果差
70
0
2021-10-17
回复
canlab
(审核中...)
关注
已关注
前往app查看评论内容
#BMS#
BMS的CAR-T细胞疗法治疗多发性骨髓瘤,已获得FDA批准
64
0
2021-03-29
回复
canlab
(审核中...)
关注
已关注
前往app查看评论内容
#BMS#
FDA接受BMS在梗阻性肥厚性心肌病(oHCM)中使用Mavacamten的申请
133
0
2021-03-23
回复
canlab
(审核中...)
关注
已关注
前往app查看评论内容
#BMS#
131亿美元!BMS完成对MyoKardia的收购,获得心血管特效药mavacamten
72
0
2020-11-20
回复
canlab
(审核中...)
关注
已关注
前往app查看评论内容
#BMS#
J Neurointerv Surg:药物涂层球囊治疗冠状动脉新生病变的效果并不劣于BMS或DES
85
0
2020-11-14
回复
canlab
(审核中...)
关注
已关注
前往app查看评论内容
#BMS#
BMS口服TYK2抑制剂deucravacitinib治疗斑块型银屑病3期临床成功! 效果优于apremilast
115
0
2020-11-07
回复
canlab
(审核中...)
关注
已关注
前往app查看评论内容
#BMS#
J Tissue Eng Regen Med:BMSCs衍生的外泌体对炎症和成骨的免疫调节作用
67
0
2020-10-09
回复
canlab
(审核中...)
关注
已关注
前往app查看评论内容
#BMS#
Cell Transplant:研究揭示αCGRP影响BMSCs迁移和成骨的机制
59
0
2020-10-05
回复
canlab
(审核中...)
关注
已关注
前往app查看评论内容
#BMS#
Biomed Res Int:研究发现镁通过调整骨免疫调控增强BMSCs的成骨作用
80
0
2020-10-05
回复
canlab
(审核中...)
关注
已关注
前往app查看评论内容
#BMS#
吉利德Kite副总裁离职、拜耳CEO任期延长、BMS肿瘤研发首脑加入Blueprint……
100
0
2020-09-21
回复
canlab
(审核中...)
关注
已关注
前往app查看评论内容
#BMS#
BMS的PD-1单抗Opdivo,获得FDA批准用于晚期食道鳞状细胞癌
78
0
2020-06-13
回复
canlab
(审核中...)
关注
已关注
前往app查看评论内容
#BMS#
Stem Cells Int:PDGF-BB可增强BMSC的成骨和血管生成能力促进骨再生
72
0
2020-05-31
回复
canlab
(审核中...)
关注
已关注
前往app查看评论内容
#BMS#
肺癌一线免疫治疗!BMS明星免疫组合Opdivo+Yervoy获美国FDA批准第5个适应症,治疗转移性非小细胞肺癌患者!
109
0
2020-05-20
回复
canlab
(审核中...)
关注
已关注
前往app查看评论内容
#BMS#
BMS的PD-1单抗Opdivo首次获批治疗食道癌
69
0
2020-02-27
回复
canlab
(审核中...)
关注
已关注
前往app查看评论内容
#BMS#
JAMA Oncol:BMS-986156单药或联合纳武单抗治疗晚期实体肿瘤
56
0
2019-11-23
回复
canlab
(审核中...)
关注
已关注
前往app查看评论内容
#BMS#
BMS的Opdivo/Yervoy组合治疗肝细胞癌,获得FDA的优先审查
94
0
2019-11-19
回复
canlab
(审核中...)
关注
已关注
前往app查看评论内容
#BMS#
BMS的PD-1单抗Opdivo联合CTLA-4单抗Yervoy治疗非小细胞肺癌中III期临床成功
62
0
2019-10-25
回复
canlab
(审核中...)
关注
已关注
前往app查看评论内容
#BMS#
BMS和辉瑞宣布与Fitbit合作推动房颤可穿戴设备的及时诊断
86
0
2019-10-21
回复
共60条
首页
上一页
下一页
尾页
页码:
1
/3页
20条/页
扫描二维码下载梅斯医学APP
map
科室
订阅+
更多科室
工具
服务
map
map